Products You May Like
The price movement was not just an indication of the company missing its Q2 revenue targets. It reflects a more fundamental shift in the ATTR-CM market that looks to be in favor of ATTR-CM stabilizers, such as Vyndamax and Attruby, over silencers like Alnylam’s Amvuttra.
Q2 earnings signal Alnylam’s ATTR-CM failure
The company surprised investors by lowering financial forecasts for Amvuttra, its most important drug franchise, by $200 million on July 30, 2026.
On the day of the announcement, the financial impact was immediate. Shares fell nearly 29% on July 30 and closed at $211.06, approaching the stock’s52-week low. Alnylam announced Amvuttra missed analyst expectations for sales by 4%, while the company lowered its full-year ATTR-CM revenue guidance to a range of $4.2 billion to $4.5 billion. This has left investors wondering about the company’s long-term prospects.
Wainua trial and stabilizer lead
A superficial reading of Alnylam’s track record suggested a promising outlook, as Amvuttra had beaten projections repeatedly since its March 2025 ATTR-CM approval. Alnylam had predicted that its ATTR-CM treatments wouldbringin $4.4 billion to $4.7 billion by 2026. However, underlying it all was the critical assumption that silencers could be more effective than stabilizers.
AstraZeneca’s recent clinical trial of its ATTR-CM silencer treatment, Wainua, disproved this. As AstraZeneca announced the results of its Phase 3 clinical trial of the drug, in partnership with Ionis, Wainua failed to demonstrate a statistically significant reduction in cardiovascular death and recurrent cardiovascular events across its study population.
At the same time, competition from stabilizer drugs, such as BridgeBio’s Attruby (acoramidis), has filled the gap in the cardiovascular market. Analystsraised2026 worldwide sales projections to over $1 billion for BridgeBio, with peak sales forecast at $3.5 billion. In addition, the Phase 3 ATTRibute-CM studydemonstrateda 50% reduction in the cumulative frequency of cardiovascular-related hospitalizations and a favorable mortality trend.
This is significant, as Alnylam has been in ahigh-stakes battleover the last year to carve out a share of the multibillion-dollar TTR cardiomyopathy market, which has become increasingly competitive due to drugs like BridgeBio’s Attruby leading the market.
The failure of AstraZeneca’s Wainua in its clinical trial points to the fact that silencer treatments, like Alnylam’s Amvuttra, are no longer the treatment of choice for clinicians. Alnylam’s financial difficulties are likely not merely a short-term price fluctuation, but a long-term structural issue that undermines Alnylam’s position in the ATTR-CM market.
US investigation by investors on Alnylam’s Q2 results
Alnylam’s damaging financial results were followed by news that the Law Offices of Frank R. Cruz, among other firms,openedan investigation into Alnylam Pharmaceuticals on behalf of investors due to concerns that the company possibly violated federal securities laws.
This investigation isattributedto the stock guidance cuts announced on July 30th, followed by the sizable drop in Alnylam’s stock price, which significantly damaged investors linked investments.
When a public company such as Alnylam, makes a significant downward revision to its stock guidance and the stock price falls sharply, investigations are common to see if the company’s previous statements were misleading, whether management knew, or should have known, that sales trends were weaker than previously communicated, and/or that investors bought shares at inflated prices based on allegedly inaccurate disclosures.
Regardless of the investigation’s results, Alnylam’s standing in the ATTR-CM market has been severely damaged, raising significant questions for investors. The picture is therefore uncertain for Alnylam Pharmaceuticals. The company’s main product, an ATTR-CM silencer (Amvuttra), has been significantly undermined, along with investors’ trust in the company. It is unclear how the stock will grow from here and how the US probe will affect the company overall.